Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients
| Autor: | Hua Lei, J.H. Huang, H.Y. Chen, Alan Geater, Jing You, Jun Liu, Bao-Zhang Tang, Yun-Li Li, Lin Zhuang, Hutcha Sriplung, Virasakdi Chongsuvivatwong |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male Hepatitis B virus Guanine Adolescent Lymphocyte CD4-CD8 Ratio Biology CD8-Positive T-Lymphocytes medicine.disease_cause Virus Replication Antiviral Agents Models Biological lcsh:Infectious and parasitic diseases Cohort Studies Hepatitis B Chronic Liver Function Tests T-Lymphocyte Subsets medicine Humans lcsh:RC109-216 Hepatitis B e Antigens Viremia Every Eight Weeks Entecavir Hepatitis B Middle Aged Viral Load medicine.disease medicine.anatomical_structure Infectious Diseases Immunology DNA Viral Multivariate Analysis Regression Analysis Female Every Four Weeks Viral load CD8 medicine.drug Research Article |
| Zdroj: | BMC Infectious Diseases BMC Infectious Diseases, Vol 8, Iss 1, p 123 (2008) |
| ISSN: | 1471-2334 |
| Popis: | BackgroundTo investigate dynamic fluctuations of serum viral load and peripheral T-lymphocyte subpopulations of chronic hepatitis B patients and their correlation during entecavir therapy.MethodsFifty-five patients received entecavir 0.5 mg/d therapy. Serum HBV DNA load was measured by Real-Time-PCR, and the levels of peripheral T-lymphocyte subpopulations by flow cytometry biweekly, every four weeks and every eight weeks during weeks 1–12, 13–24 and 24–48, respectively. Multilevel modelling was used to analyse the relationship between these variables.ResultsOf the 55 patients, all HBeAg positive and with detectable HBV DNA, the majority (81.8%) had serum levels of HBV DNA over 107copies per milliliter. HBV viral load dropped sharply during the first two weeks. In 28 and 43 patients, the level became undetectable from week 24 and 48, respectively. Using pre-therapy level as the reference, a significant decrease in CD8+T cells and increase in CD4+T cells were found from week 12. Both parameters and CD4+/CD8+ratio steadily improved throughout the 48 weeks. Multilevel analyses showed that the level of decrement of HBV DNA was associated with the increment of T-lymphocyte activities only in the later period (4–48 week). After 4 weeks of therapy, for each log10scale decrement of HBV DNA, the percentage of CD4+lymphocyte was increased by 0.49 and that of CD8+decreased by 0.51.ConclusionT-lymphocyte subpopulations could be restored partially by entecavir treatment in patients with chronic hepatitis B concurrently with reduction of viremia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink